LRP1B associated with immune cell infiltration influenced the efficacy of immunotherapy in colorectal cancer patients.

IF 2.2 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Clinics Pub Date : 2024-11-11 eCollection Date: 2024-01-01 DOI:10.1016/j.clinsp.2024.100516

Weiming Weng, Shengquan He, Guoxiong Zhang, Xindong Zhou, Kang Li, Jiajun Lai

{"title":"LRP1B associated with immune cell infiltration influenced the efficacy of immunotherapy in colorectal cancer patients.","authors":"Weiming Weng, Shengquan He, Guoxiong Zhang, Xindong Zhou, Kang Li, Jiajun Lai","doi":"10.1016/j.clinsp.2024.100516","DOIUrl":null,"url":null,"abstract":"Objective: Colorectal cancer is one of the most common malignant tumors in the world, which seriously threatens human health. It is essential for the search for new oncogene targets in colorectal cancer.Methods: Samples from 57 colorectal cancer patients were collected in this study. Next-Generation Sequencing (NGS) was performed to detect gene mutation, assess Microsatellite Instability (MSI), and evaluate Tumor Mutational Burden (TMB). RNA data from 528 CRC patients from the TCGA database were analyzed.Results: A total of 57 colon cancer patients were included in this study, including 30 males and 27 females, with a mean age of 56 years. In this study, the most common mutations were APC (79 %), TP53 (61 %), TTN (48 %), KRAS (42 %), SYNE1 (28 %), MUC16 (25 %), PIK3CA (25 %), FAT4 (22 %), RYR2 (19 %), OBSCN (18 %), and ZFHX4 (18 %). Subsequently, the authors analyzed gene mutations in colorectal cancer patients according to gender, age, and TMB status. Significant differences in immune cell infiltration were found between colorectal cancer tissues and normal tissues by CIBERSORT analysis. LRP1B may serve as a potential colorectal cancer therapeutic target, and its absence leads to changes in immune cell infiltration.Conclusion: The authors described the molecular characteristics of CRC. Loss of LRP1B leads to changes in immune cell infiltration and can be used as a therapeutic target for colorectal cancer.","PeriodicalId":10472,"journal":{"name":"Clinics","volume":"79 ","pages":"100516"},"PeriodicalIF":2.2000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clinsp.2024.100516","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Colorectal cancer is one of the most common malignant tumors in the world, which seriously threatens human health. It is essential for the search for new oncogene targets in colorectal cancer.

Methods: Samples from 57 colorectal cancer patients were collected in this study. Next-Generation Sequencing (NGS) was performed to detect gene mutation, assess Microsatellite Instability (MSI), and evaluate Tumor Mutational Burden (TMB). RNA data from 528 CRC patients from the TCGA database were analyzed.

Results: A total of 57 colon cancer patients were included in this study, including 30 males and 27 females, with a mean age of 56 years. In this study, the most common mutations were APC (79 %), TP53 (61 %), TTN (48 %), KRAS (42 %), SYNE1 (28 %), MUC16 (25 %), PIK3CA (25 %), FAT4 (22 %), RYR2 (19 %), OBSCN (18 %), and ZFHX4 (18 %). Subsequently, the authors analyzed gene mutations in colorectal cancer patients according to gender, age, and TMB status. Significant differences in immune cell infiltration were found between colorectal cancer tissues and normal tissues by CIBERSORT analysis. LRP1B may serve as a potential colorectal cancer therapeutic target, and its absence leads to changes in immune cell infiltration.

Conclusion: The authors described the molecular characteristics of CRC. Loss of LRP1B leads to changes in immune cell infiltration and can be used as a therapeutic target for colorectal cancer.

查看原文本刊更多论文

与免疫细胞浸润相关的 LRP1B 会影响结直肠癌患者免疫疗法的疗效。

目的：大肠癌是世界上最常见的恶性肿瘤之一，严重威胁人类健康：大肠癌是世界上最常见的恶性肿瘤之一，严重威胁人类健康。寻找结直肠癌新的癌基因靶点至关重要：方法：本研究收集了 57 名结直肠癌患者的样本。方法：本研究收集了 57 名结直肠癌患者的样本，并进行了下一代测序（NGS），以检测基因突变、评估微卫星不稳定性（MSI）和肿瘤突变负荷（TMB）。对 TCGA 数据库中 528 例 CRC 患者的 RNA 数据进行了分析：本研究共纳入了 57 例结肠癌患者，其中男性 30 例，女性 27 例，平均年龄 56 岁。在这项研究中，最常见的突变是 APC（79%）、TP53（61%）、TTN（48%）、KRAS（42%）、SYNE1（28%）、MUC16（25%）、PIK3CA（25%）、FAT4（22%）、RYR2（19%）、OBSCN（18%）和 ZFHX4（18%）。随后，作者根据性别、年龄和 TMB 状态分析了结直肠癌患者的基因突变情况。通过 CIBERSORT 分析发现，结直肠癌组织与正常组织的免疫细胞浸润存在显著差异。LRP1B可能是结直肠癌的潜在治疗靶点，它的缺失会导致免疫细胞浸润的变化：作者描述了 CRC 的分子特征。结论：作者描述了 CRC 的分子特征，LRP1B 的缺失会导致免疫细胞浸润的变化，可作为结直肠癌的治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinics 医学-医学：内科

CiteScore

4.10

自引率

3.70%

发文量

129

审稿时长

52 days

期刊介绍： CLINICS is an electronic journal that publishes peer-reviewed articles in continuous flow, of interest to clinicians and researchers in the medical sciences. CLINICS complies with the policies of funding agencies which request or require deposition of the published articles that they fund into publicly available databases. CLINICS supports the position of the International Committee of Medical Journal Editors (ICMJE) on trial registration.